Great Lakes Advisors LLC Has $4 Million Holdings in Orthofix Medical Inc. (NASDAQ:OFIX)

Great Lakes Advisors LLC trimmed its position in Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) by 7.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 229,274 shares of the medical device company's stock after selling 17,283 shares during the quarter. Great Lakes Advisors LLC owned about 0.60% of Orthofix Medical worth $4,003,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the stock. HighVista Strategies LLC bought a new stake in Orthofix Medical in the 3rd quarter valued at $1,689,000. JPMorgan Chase & Co. grew its holdings in Orthofix Medical by 480.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 84,379 shares of the medical device company's stock worth $1,318,000 after acquiring an additional 69,848 shares during the last quarter. Millrace Asset Group Inc. bought a new stake in Orthofix Medical during the 3rd quarter worth about $906,000. Raymond James Financial Inc. bought a new stake in Orthofix Medical during the 4th quarter worth about $1,003,000. Finally, HighTower Advisors LLC lifted its position in Orthofix Medical by 114.9% during the 3rd quarter. HighTower Advisors LLC now owns 89,183 shares of the medical device company's stock valued at $1,393,000 after purchasing an additional 47,680 shares during the period. 89.76% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Orthofix Medical

In other news, CEO Massimo Calafiore sold 10,078 shares of Orthofix Medical stock in a transaction on Friday, January 10th. The stock was sold at an average price of $16.83, for a total transaction of $169,612.74. Following the completion of the sale, the chief executive officer now owns 133,354 shares of the company's stock, valued at approximately $2,244,347.82. This trade represents a 7.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Julie Andrews sold 4,655 shares of Orthofix Medical stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $17.89, for a total value of $83,277.95. Following the sale, the chief financial officer now directly owns 28,312 shares of the company's stock, valued at $506,501.68. This represents a 14.12 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 25,416 shares of company stock valued at $436,419 in the last quarter. 2.60% of the stock is currently owned by insiders.

Remove Ads

Orthofix Medical Stock Up 0.9 %

Shares of NASDAQ:OFIX traded up $0.15 during midday trading on Wednesday, hitting $16.75. The stock had a trading volume of 296,699 shares, compared to its average volume of 195,692. Orthofix Medical Inc. has a 12 month low of $12.08 and a 12 month high of $20.73. The company has a quick ratio of 1.11, a current ratio of 2.39 and a debt-to-equity ratio of 0.25. The business's 50-day simple moving average is $17.79 and its 200-day simple moving average is $17.38. The company has a market cap of $653.62 million, a P/E ratio of -5.35 and a beta of 1.06.

Analysts Set New Price Targets

OFIX has been the topic of a number of research reports. Roth Mkm restated a "buy" rating and set a $22.00 target price on shares of Orthofix Medical in a research report on Wednesday, February 26th. Canaccord Genuity Group reissued a "buy" rating and set a $24.00 target price on shares of Orthofix Medical in a research note on Wednesday, February 26th. Finally, StockNews.com raised shares of Orthofix Medical from a "hold" rating to a "buy" rating in a research note on Tuesday, February 25th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, Orthofix Medical currently has an average rating of "Moderate Buy" and a consensus price target of $23.33.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.